Lubabegron
{{Short description|Drug}}
{{Infobox drug
| drug_name =
| INN =
| type =
| image = Lubabegron.svg
| alt =
| caption =
| pronounce =
| tradename = Experior
| Drugs.com =
| MedlinePlus =
| pregnancy_AU =
| pregnancy_AU_comment =
| pregnancy_category=
| routes_of_administration =
| ATCvet =
| ATC_prefix = None
| ATC_suffix =
| legal_AU =
| legal_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA =
| legal_CA_comment =
| legal_DE =
| legal_DE_comment =
| legal_NZ =
| legal_NZ_comment =
| legal_UK =
| legal_UK_comment =
| legal_US =
| legal_US_comment =
| legal_EU =
| legal_EU_comment =
| legal_UN =
| legal_UN_comment =
| legal_status = Veterinary use only
| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life =
| duration_of_action=
| excretion =
| CAS_number = 391920-32-4
| PubChem = 60085980
| ChemSpiderID = 28536141
| DrugBank =
| UNII = 8501207BZX
| KEGG = D10445
| synonyms = LY-488756
| IUPAC_name = 2-[4-[2-
| C=29|H=29|N=3|O=3|S=1
}}
Lubabegron (trade name Experior) is a veterinary drug used to reduce ammonia emissions from animals and their waste.{{Cite web | url=https://www.avma.org/javma-news/2019-01-15/drug-reduces-ammonia-cattle-waste | title = Drug reduces ammonia in cattle waste | publisher = American Veterinary Medical Association | date = December 31, 2018}} Ammonia emissions are a concern in agricultural production because of detrimental effects on the environment, human health, and animal health.{{Cite web | url = https://ohioline.osu.edu/factsheet/AEX-723.1 | title = Ammonia Emission from Animal Feeding Operations and Its Impacts | publisher = Ohio State University Extension | date = May 16, 2014 }}
Lubabegron was approved by the U.S. Food and Drug Administration in 2018 for use in feedlot cattle.{{cite journal | vauthors = Kube JC, Holland BP, Word AB, Allen JB, Calvo-Lorenzo M, McKenna D, Vogel G | title = Effects of various doses of lubabegron on calculated ammonia gas emissions, growth performance, and carcass characteristics of beef cattle during the last 56 days of the feeding period | journal = Translational Animal Science | volume = 5 | issue = 3 | pages = txab137 | date = July 2021 | pmid = 34532643 | pmc = 8439260 | doi = 10.1093/tas/txab137 }}{{cite journal | vauthors = Teeter JS, Werth SJ, Gruber SL, Kube JC, Hagenmaier JA, Allen JB, Herr CT, Brown MS, Boler D, Dilger AC, Zhao Y, Pan Y, Mitloehner FM | display-authors = 6 | title = Effects of feeding lubabegron on gas emissions, growth performance, and carcass characteristics of beef cattle housed in small-pen environmentally monitored enclosures during the last 3 mo of the finishing period | journal = Journal of Animal Science | volume = 99 | issue = 12 | date = December 2021 | pmid = 34849995 | pmc = 8668178 | doi = 10.1093/jas/skab338 }} It is the first drug approved for reducing ammonia emissions.{{Cite journal|url=https://www.fda.gov/news-events/fda-voices/advancing-development-innovative-veterinary-products|archive-url=https://web.archive.org/web/20211005142117/https://www.fda.gov/news-events/fda-voices/advancing-development-innovative-veterinary-products|url-status=dead|archive-date=October 5, 2021|title = Advancing the Development of Innovative Veterinary Products|journal = FDA|date = 5 October 2021}} It is also approved for use in Canada.{{Cite web | url=https://inspection.canada.ca/animal-health/livestock-feeds/medicating-ingredients/lubabegron/eng/1547583000099/1547583001862 | title = Lubabegron (LBGF) - Medicating Ingredient Brochure | date = 22 January 2019 | publisher = Government of Canada }}
Lubabegron is a beta-adrenergic receptor agonist/antagonist.{{cite web | url = https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/5005 | title = Freedom of Information Summary: Original New Animal Drug Application }} The antagonist activity of lubabegron at β1 and β2 receptors prevents the stimulation of the β-AR found in the heart (β1) and trachea/bronchi (β2) of humans and, in doing so, avoids the potential negative side effects associated with β1 and β2 receptor activation. The β1-AR and β2-AR antagonist behavior of lubabegron could decrease lipolysis in adipose tissue, whereas the β3-AR agonist activity could increase skeletal muscle hypertrophy, possibly due to the differences in the second messenger systems and enzyme expression in skeletal muscle compared with adipose tissues.{{cite journal | vauthors = Dilger AC, Johnson BJ, Brent P, Ellis RL | title = Comparison of beta-ligands used in cattle production: structures, safety, and biological effects | journal = Journal of Animal Science | volume = 99 | issue = 8 | date = August 2021 | pmid = 34337648 | pmc = 8326055 | doi = 10.1093/jas/skab094 }}